ATE524190T1 - INHIBITION OF CHOLERA TOXINS BY GALATOOLIGOSACCHARIDES (GOS) - Google Patents

INHIBITION OF CHOLERA TOXINS BY GALATOOLIGOSACCHARIDES (GOS)

Info

Publication number
ATE524190T1
ATE524190T1 AT07834613T AT07834613T ATE524190T1 AT E524190 T1 ATE524190 T1 AT E524190T1 AT 07834613 T AT07834613 T AT 07834613T AT 07834613 T AT07834613 T AT 07834613T AT E524190 T1 ATE524190 T1 AT E524190T1
Authority
AT
Austria
Prior art keywords
gos
galatooligosaccharides
inhibition
nutritional
cholera toxin
Prior art date
Application number
AT07834613T
Other languages
German (de)
Inventor
Haydn Robert Sinclair
Slegte Jaap De
Gijsbertus Klarenbeek
Original Assignee
Friesland Brands Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Friesland Brands Bv filed Critical Friesland Brands Bv
Application granted granted Critical
Publication of ATE524190T1 publication Critical patent/ATE524190T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

The invention relates to nutritional and pharmaceutical compositions comprising non-digestible galactooligosaccharides (GOS) and uses thereof. In particular, it relates to the use of GOS species in preventing or treating disease caused by bacterial toxins. Provided is the use of GOS having a polymerization degree of 5 or higher, preferably 6 or higher, for the manufacture of a nutritional or pharmaceutical composition for the treatment or prevention of an acute or chronic disease associated with or caused by the adhesion and/or uptake of a cholera toxin family member. Also provided is a method for providing a GOS fraction capable of inhibiting cholera toxin (Ctx) binding to GM1 and fractions obtainable thereby.
AT07834613T 2006-10-02 2007-10-01 INHIBITION OF CHOLERA TOXINS BY GALATOOLIGOSACCHARIDES (GOS) ATE524190T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06076810 2006-10-02
PCT/NL2007/050475 WO2008041843A1 (en) 2006-10-02 2007-10-01 Inhibition of cholera toxins by galatooligosaccharides (gos)

Publications (1)

Publication Number Publication Date
ATE524190T1 true ATE524190T1 (en) 2011-09-15

Family

ID=37533486

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07834613T ATE524190T1 (en) 2006-10-02 2007-10-01 INHIBITION OF CHOLERA TOXINS BY GALATOOLIGOSACCHARIDES (GOS)

Country Status (10)

Country Link
US (1) US8202842B2 (en)
EP (1) EP2076271B1 (en)
JP (1) JP2010505822A (en)
AT (1) ATE524190T1 (en)
DK (1) DK2076271T3 (en)
ES (1) ES2373592T3 (en)
PL (1) PL2076271T3 (en)
PT (1) PT2076271E (en)
SI (1) SI2076271T1 (en)
WO (1) WO2008041843A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006012536A2 (en) 2004-07-22 2006-02-02 Ritter Andrew J Methods and compositions for treating lactose intolerance
FR2907687B1 (en) * 2006-10-30 2008-12-26 Applexion PROCESS FOR PURIFYING SIALYLLACTOSE BY CHROMATOGRAPHY
US20110223248A1 (en) * 2007-12-12 2011-09-15 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
EP2400839B1 (en) 2009-02-24 2016-09-07 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
WO2010105207A1 (en) † 2009-03-13 2010-09-16 The Regents Of The University Of California Prebiotic oligosaccharides
US20110189342A1 (en) * 2010-02-01 2011-08-04 Jeong Hea-Seok High-purity galactooligosaccharides and uses thereof
EP3202406A1 (en) 2010-04-28 2017-08-09 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
NL2007931C2 (en) * 2011-12-07 2013-06-10 Friesland Brands Bv Methods for providing sialylated oligosaccharides and products obtainable thereby.
WO2015095747A1 (en) 2013-12-20 2015-06-25 Abbott Laboratories Oral rehydration composition with oligosaccharides
EP3530743A1 (en) 2018-02-21 2019-08-28 Cambridge Glycoscience Ltd Method of production
EP3836802A1 (en) 2018-08-15 2021-06-23 Cambridge Glycoscience Ltd Novel compositions, their use, and methods for their formation
CA3108735A1 (en) 2018-09-06 2020-03-12 Frieslandcampina Nederland B.V. Bifidogenic hypoallergenic gos compositions and methods for providing the same involving beta-galactosidase from a strain of lactobacillus delbrueckii ssp bulgaricus
KR102874614B1 (en) * 2018-11-08 2025-10-22 디에스엠 아이피 어셋츠 비.브이. How to regulate gastric metabolites
ES2987615T3 (en) * 2018-11-08 2024-11-15 Dsm Ip Assets Bv Methods to selectively modulate gastrointestinal microbial growth
JP7672391B2 (en) 2019-08-16 2025-05-07 ケンブリッジ グリコサイエンス エルティーディー Methods for processing biomass to produce oligosaccharides and related compositions
EP4072318A2 (en) 2019-12-12 2022-10-19 Cambridge Glycoscience Ltd Low sugar multiphase foodstuffs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0614870B2 (en) * 1986-12-15 1994-03-02 株式会社ヤクルト本社 Method for producing galactooligosaccharide
NZ222902A (en) 1986-12-15 1990-08-28 Yakult Honsha Kk Method for producing galactooligosaccharide
ZA991410B (en) 1998-02-23 1999-10-06 Synsorb Biotech Inc Compounds and methods for the treatment of bacterial dysentry using antibiotics and toxin binding oligosaccharide compositions.
US6630452B2 (en) * 2000-02-17 2003-10-07 Wyeth Nutritional formulation containing prebiotic substances
FR2838452B1 (en) * 2002-04-10 2004-07-09 Eurodia Ind PROCESS FOR THE CONTINUOUS PRODUCTION OF GALACTO OLIGOSACCHARIDES
GB0229015D0 (en) * 2002-12-12 2003-01-15 Novartis Nutrition Ag New Compound
GB0308104D0 (en) 2003-04-08 2003-05-14 Novartis Nutrition Ag Organic compounds
KR100857500B1 (en) 2003-06-30 2008-09-08 클라사도 인크. Novel galactooligosaccharide composition and the preparation thereof
US8562712B2 (en) 2003-07-04 2013-10-22 Commonwealth Sci. and Ind. Res. Org. Method and apparatus for the production of metal compounds
AU2004280375B2 (en) * 2003-10-02 2008-05-15 Nestec S.A. Prebiotic effect analysis

Also Published As

Publication number Publication date
PL2076271T3 (en) 2012-02-29
WO2008041843A1 (en) 2008-04-10
DK2076271T3 (en) 2012-01-16
EP2076271A1 (en) 2009-07-08
US20100069322A1 (en) 2010-03-18
PT2076271E (en) 2011-12-02
JP2010505822A (en) 2010-02-25
EP2076271B1 (en) 2011-09-14
US8202842B2 (en) 2012-06-19
ES2373592T3 (en) 2012-02-06
SI2076271T1 (en) 2011-12-30

Similar Documents

Publication Publication Date Title
ATE524190T1 (en) INHIBITION OF CHOLERA TOXINS BY GALATOOLIGOSACCHARIDES (GOS)
WO2004103294A3 (en) Methods and compositions for the prevention and treatment of sepsis
BR0304648A (en) Combination of cyclooxygenase-2 inhibitors and thalidomide for the treatment of neoplasia
TW200740849A (en) Dual variable domain immunoglobulin and uses thereof
ATE375164T1 (en) ENDOTOXIN BINDING BY LACTIC ACID BACTERIA AND BIFIDOBACTERIA
WO2006128032A3 (en) Compositions and methods for the prevention and treatment of conditions associated with inflammation
MY147489A (en) Methods for the treatment of muscle loss
BRPI0616960B8 (en) use of lactobacillus for the treatment of viral infections
EA200870594A1 (en) BINDING HUMAN MOLECULES WITH KILLER ACTIVITY AGAINST ENTEROCCOKKKI AND THEIR APPLICATION
WO2007103114A3 (en) Notch inhibition in the treatment or prevention of atherosclerosis
BRPI0722054A2 (en) COMPOSITION, KIT, AND METHODS TO REDUCE A SIDE TREATMENT EFFECT WITH A CALCINEURIN INHIBITOR, TO INCREASE A THERAPEUTIC EFFECT OF A CALCINEURIN INHIBITOR AND TO CHANGE THE CONCENTRATION OF TACROLIMUS OR ANALYLOGAL ANALOGUE
ATE537819T1 (en) NUTRACEUTICAL COMPOSITIONS FOR TREATING MUSCLE WASTING
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
MX2008000064A (en) Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (rbp), and/or serum retinol-rbp modulation.
WO2007100765A3 (en) Lysozyme-modified probiotic components and uses thereof
WO2008008772A3 (en) Methods for treating and limiting fibrotic disorders and keloids
WO2022058618A3 (en) Sars-cov2 antibodies
DK2208734T3 (en) Food material to inhibit osteoclast formation
WO2008059041A3 (en) Complementation of factor xi deficiency by factor v mutants
DE602004005455D1 (en) METHOD FOR TREATING OR PREVENTING CHRONIC WOUNDS AND COMPLETE FOOD COMPOSITION WITH GLYCIN AND / OR LEUCINE FOR USE THEREIN
ATE473277T1 (en) COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES
EP2500355A3 (en) Dual variable domain immunoglobulin and uses thereof
WO2008063853A3 (en) Cancer treatment method
EA201200182A1 (en) BINDING HUMAN MOLECULES WITH KILLER ACTIVITY AGAINST ENTEROCCOKKKI AND THEIR APPLICATION
TH99129A (en) Inhibition of cholera toxins By galactose olixaccharides

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties